SAN DIEGO, CA USA (UroToday.com) - Emerging pay-for-performance reimbursement mechanisms are directed at improving delivery of high-quality, valued-based care while reducing unnecessary utilization and expenditures.
A lack of level one evidence has limited development of rigorous metrics to reliably measure quality for patients undergoing surgical treatment of muscle invasive bladder cancer (MIBC), and current proposed performance measures are largely based on expert opinion. Our aim was to assess trends in performance of candidate quality measures in patients undergoing RC for MIBC, by hospital type, using a large national tumor registry.
Presented by Anthony T. Corcoran,1 Elizabeth Handorf,2 Dan Canter,3 Justin E. Bekelman,4 Simon P Kim,5 Robert G. Uzzo,1 Alexander Kutikov,1 and Marc C. Smaldone1 at the American Urological Association (AUA) Annual Meeting - May 4 - 8, 2013 - San Diego Convention Center - San Diego, California USA
Division of Urologic Oncology,1 Biostatistics & Bioinformatics Facility,2 Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA; Department of Urology,3 Emory University School of Medicine, Atlanta, GA; Department of Radiation Oncology,4 University of Pennsylvania School of Medicine, Philadelphia, PA; Department of Urology,5 Mayo Clinic, Rochester, MN
